首页> 外文期刊>Clinical rheumatology >Accuracy of semiquantitative immunoenzymatic methods in quantitation of anti-topoisomerase I (Scl-70) antibodies.
【24h】

Accuracy of semiquantitative immunoenzymatic methods in quantitation of anti-topoisomerase I (Scl-70) antibodies.

机译:半定量免疫酶法定量抗拓扑异构酶I(Scl-70)抗体的准确性。

获取原文
获取原文并翻译 | 示例
           

摘要

Reports of a possible correlation between anti-Scl-70 antibody concentration and clinical manifestations in systemic sclerosis patients have recently appeared in the scientific literature. The goal of our study was to evaluate, by means of a multicenter study, the analytical reliability of immunoassay systems in the quantitative measurement of Scl-70 antibodies. Three blind samples (H, M, L) at different anti-Scl-70 antibody concentrations, and a low concentration antibody serum (LPC) used as a common calibrator, were sent three times in a 6-month time span to 39 Italian clinical laboratories. Each laboratory was asked to calculate dosages following the enzyme-linked immunosorbent assay (ELISA) method they used and report the optical density values of each sample (ODs), of the cutoff serum provided by the manufacturer of the kit used (ODco) and of LPC (ODLPC). The overall analytical imprecision (between methods and between laboratories) of the three different determinations of the values respectively expressed in ODs, ODs/ODco and ODs/ODLPCratio was 47.1, 52.8 and 34.0% for sample H, 56.2, 47.4% and 34% for sample M and 84.6, 86.0 and 86.6% for sample L. The average intra-method analytical imprecision was, respectively, 20.7, 29.8 and 18.6% for sample H, 24.6, 26.5 and 19.3% for sample M, and 30.6, 28.1 and 20.2% for sample L. The commercial ELISA methods currently used to determine the presence of anti-Scl-70 autoantibodies show considerable differences in the quantitative determination. The best results for reproducibility analyses have been obtained when the values were expressed as a ratio between the ODs of the sample and of the common calibrator (ODs/ODLPC). Forward-looking clinical studies that can clarify the usefulness of quantitative determination of anti-Scl-70 antibodies in the monitoring of diffuse scleroderma patients can be performed only when standard serum with a known antibody concentration and calibration curves for quantitative ELISA measurements are made available.
机译:科学文献中最近出现了关于系统性硬化症患者中抗Scl-70抗体浓度与临床表现之间可能相关性的报道。我们研究的目的是通过多中心研究评估免疫测定系统在Scl-70抗体定量检测中的分析可靠性。将三个不同抗Scl-70抗体浓度的盲样品(H,M,L)和用作普通校准品的低浓度抗体血清(LPC)在6个月的时间内发送给了39意大利临床实验室。要求每个实验室按照他们使用的酶联免疫吸附测定(ELISA)方法计算剂量,并报告每个样品(ODs),所用试剂盒制造商(ODco)提供的截止血清的光学密度值以及LPC(ODLPC)。三种不同测定值的分别以ODs,ODs / ODco和ODs / ODLPCr表示的三种方法的总分析误差(样品H的分别为47.1%,52.8%和34.0%,H样品的56.2%,47.4%和34%)样本M和样本L分别为84.6、86.0和86.6%。方法内的平均方法内分析不准确度分别为:样本H为20.7、29.8和18.6%,样本M为24.6、26.5和19.3%,以及30.6、28.1和20.2目前,用于确定抗Scl-70自身抗体存在的商业ELISA方法在定量测定中显示出很大差异。当值表示为样品和普通校准品的OD之比(ODs / ODLPC)时,可获得最佳的重现性分析结果。仅当具有已知抗体浓度的标准血清和用于定量ELISA测量的校准曲线可用时,才能进行前瞻性临床研究,以阐明定量测定抗Scl-70抗体在监测弥漫性硬皮病中的有用性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号